Olanzapine and Monocyte count increased - a phase IV clinical study of FDA data

Summary:

Monocyte count increased is reported as a side effect among people who take Olanzapine (olanzapine), especially for people who are female, 60+ old, also take Clozaril, and have Schizoaffective disorder.

The phase IV clinical study analyzes which people have Monocyte count increased when taking Olanzapine. It is created by eHealthMe based on reports of 68,588 people who have side effects when taking Olanzapine from the FDA, and is updated regularly.

What is Olanzapine?

Olanzapine has active ingredients of olanzapine. It is often used in bipolar disorder. eHealthMe is studying from 69,242 Olanzapine users. Check the latest studies of Olanzapine.

What is Monocyte count increased?

Monocyte count increased is found to be associated with 602 drugs and 690 conditions by eHealthMe. Check the latest studies of Monocyte count increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

68,588 people reported to have side effects when taking Olanzapine.
Among them, 82 people (0.12%) have Monocyte count increased.

Could Olanzapine cause Monocyte count increased?

Among these 82 people:

What is the gender of people who have Monocyte count increased when taking Olanzapine? *

female: 63.29 %
male: 36.71 %

What is the age of people who have Monocyte count increased when taking Olanzapine? *

What are other drugs people take besides Olanzapine? *

What are other side effects people have besides Monocyte count increased? *

Mean Cell Haemoglobin Concentration Decreased (less concentration of haemoglobin in a given volume of packed red blood cells): 43 people, 52.44%
Mean Cell Haemoglobin Decreased (less than normal haemoglobin per red blood cell in a sample of blood): 43 people, 52.44%
Drug Resistance (reduction in effectiveness of a drug): 42 people, 51.22%
Schizoaffective Disorder (a mental disorder characterized by disordered thought): 35 people, 42.68%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 18 people, 21.95%
Neutrophil Count Increased (excess than normal number of neutrophil a type of blood cell): 15 people, 18.29%
White Blood Cell Count Increased: 12 people, 14.63%
Lymphocyte Count Increased: 12 people, 14.63%
Haemoglobin Decreased: 9 people, 10.98%
Haematocrit Decreased: 8 people, 9.76%

What are the existing conditions these people have? *

Schizoaffective Disorder (a mental disorder characterized by disordered thought): 38 people, 46.34%
Schizoaffective Disorder Depressive Type (mental illness featuring schizophrenia and a mood disorder): 32 people, 39.02%
Agitation (state of anxiety or nervous excitement): 4 people, 4.88%
Psychotic Disorder: 3 people, 3.66%
Constipation: 3 people, 3.66%
Schizophrenia, Paranoid Type (delusions and auditory hallucinations but relatively normal intellectual functioning and expression of affect): 2 people, 2.44%
Affective Disorder (mental disorder): 2 people, 2.44%
Schizophrenia, Disorganised Type (speech and behaviour that are disorganized or difficult to understand): 1 person, 1.22%
Salivary Hypersecretion (excess saliva secretion): 1 person, 1.22%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 1.22%

* Approximation only. Some reports may have incomplete information.

Do you take Olanzapine and have Monocyte count increased?

- Check whether Monocyte count increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Olanzapine:

Olanzapine (69,242 reports)

Browse all side effects of Olanzapine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Monocyte count increased:

Monocyte count increased (602 drugs)

Browse all the conditions that are associated with Monocyte count increased:

Monocyte count increased (690 conditions)

Related publications that referenced our studies

Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Og?odek E, Szota A, Araszkiewicz A, "Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment", Aust NZJ Psychiatry, 2013 Oct .
Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Og?odek E, Szota A, Araszkiewicz A, "Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment", Aust NZJ Psychiatry, 2013 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on olanzapine (the active ingredients of Olanzapine) and Olanzapine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.